Sphera Funds Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Sphera Funds Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,689	Closed	-$699K	–	103
2023 Q1	$699K	Buy	+7,689	New	+$451K	0.12%	72
2020 Q4	–	Sell	-59,139	Closed	-$5.76M	–	134
2020 Q3	$5.76M	Sell	59,139 -22,910	-28%	-$2.86M	0.57%	51
2020 Q2	$12.8M	Buy	+82,049	New	+$12.5M	1.2%	20
2019 Q4	–	Sell	-63,269	Closed	-$5.08M	–	100
2019 Q3	$5.08M	Sell	63,269 -49,500	-44%	-$4.2M	0.78%	41
2019 Q2	$10.6M	Buy	112,769 +31,000	+38%	+$2.68M	1.46%	17
2019 Q1	$6.99M	Sell	81,769 -139,500	-63%	-$11.6M	0.64%	34
2018 Q4	$12.4M	Buy	221,269 +128,550	+139%	+$7.85M	1.4%	18
2018 Q3	$7.58M	Sell	92,719 -43,325	-32%	-$3.05M	0.87%	28
2018 Q2	$4.76M	Sell	136,044 -88,956	-40%	-$2.71M	0.66%	41
2018 Q1	$4.62M	Hold	225,000	–	–	0.7%	46
2017 Q4	$6.37M	Buy	225,000 +20,000	+10%	+$558K	0.75%	28
2017 Q3	$6.38M	Buy	+205,000	New	+$6.17M	0.91%	24

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's RETA Position: Q2 2023 in Review

Sphera Funds Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 7,689 shares — an estimated $699K sold.

Sphera Funds Management first reported a position in RETA in Q3 2017 and held it in 12 quarters. The position peaked at $12.8M in Q2 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Sphera Funds Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Sphera Funds Management sold 7,689 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $699K.
Sphera Funds Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 12 quarters.
Sphera Funds Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.8M in Q2 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.